Elobixibat for Chronic Constipation Without Defecation Desire

Inclusion Criteria: At the time of provisional registration * Patients diagnosed with chronic constipation using the Rome IV criteria for the diagnosis of chronic constipation * Age: 20 years or older (at the time of obtaining consent) * Gender: Any * outpatients * Patients for whom written consent can be obtained * Patients who can record defecation, etc. in the patient diary At the time of registration: Dosing start criteria Patients with the following ・'Loss of defecation desire'\* in the second week of the observation period (1 week before the start of the treatment period) \*"Loss of defecation desire " refers to patients whose "presence or absence of defecation desire" on the patient questionnaire was "4. almost never" or "5. never". Exclusion Criteria: At the time of temporary registration Exclude patients with any of the following conditions * Patients with organ-related constipation or suspected of having organ-related constipation * Patients with or suspected of having functional ileus * Patients with or suspected of having inguinal hernia * Patients with a history of open abdominal surgery within 12 weeks prior to obtaining consent (excluding appendicitis resection) * Patients with a history of surgical or endoscopic procedures related to gallbladder resection and papillotomy * Patients with complications of malignancy However, patients who have undergone radical surgery or who have completed chemotherapy or radiotherapy may be registered. * Pregnant women, lactating women, women who may be currently pregnant, or patients who cannot give consent to use contraception while participating in the study * Patients with serious renal, hepatic, or cardiac disease * Patients with drug allergy to the study drug * Patients who are participating in other clinical studies, or who have participated in other clinical studies within 4 weeks prior to obtaining consent However, observational studies are excluded. * Other patients who are judged by the principal investigator or sub-investigator to be inappropriate for this study. At the time of registration: Dosing start criteria * Patients who increased the dose of concomitantly restricted drugs during the observation period * Patients who used concomitantly prohibited drugs during the observation period